Protein tyrosine phosphatase 1B ( PTP1B ) function, structure, and inhibition strategies to develop antidiabetic drugs
FEBS Letters · 2024-08 · 598 (15) · 1811-1838
DOI: 10.1002/1873-3468.14901 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift FEBS Letters, online erschienen am 09.05.2024. Verfasst von Andrea Coronell-Tovar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Biosensores y Modelaje molecular, Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de…. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 1, Hypoglycemic Agents, Enzyme Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DGTIC-UNAM, Research Division of the Medical School, UNAM, DGAPA-UNAM.
Abstract (Originalsprache)
Tyrosine protein phosphatase non‐receptor type 1 (PTP1B; also known as protein tyrosine phosphatase 1B) is a member of the protein tyrosine phosphatase (PTP) family and is a soluble enzyme that plays an essential role in different physiological processes, including the regulation of metabolism, specifically in insulin and leptin sensitivity. PTP1B is crucial in the pathogenesis of type 2 diabetes mellitus and obesity. These biological functions have made PTP1B validated as an antidiabetic and anti‐obesity, and potentially anticancer, molecular target. Four main approaches aim to inhibit PTP1B: orthosteric, allosteric, bidentate inhibition, and PTPN1 gene silencing. Developing a potent and selective PTP1B inhibitor is still challenging due to the enzyme's ubiquitous expression, subcellular location, and structural properties. This article reviews the main advances in the study of PTP1B since it was first isolated in 1988, as well as recent contextual information related to the PTP family to which this protein belongs. Furthermore, we offer an overview of the role of PTP1B in diabetes and obesity, and the challenges to developing selective, effective, potent, bioavailable, and cell‐permeable compounds that can inhibit the enzyme.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Biosensores y Modelaje molecular, Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.
- Instituto de Química, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.
ORCID-Profile: Adela Rodríguez-Romero, Martin González-Andrade
Förderung
- DGTIC-UNAM
- Research Division of the Medical School, UNAM
- DGAPA-UNAM
Zitieren
APA
Coronell-Tovar, A., Pardo, J. P., Rodríguez-Romero, A., Sosa-Peinado, A., Vásquez-Bochm, L., Cano-Sánchez, P., Álvarez-Añorve, L. I., & González-Andrade, M. (2024). Protein tyrosine phosphatase 1B ( PTP1B ) function, structure, and inhibition strategies to develop antidiabetic drugs. FEBS Letters, 598(15), 1811-1838. https://doi.org/10.1002/1873-3468.14901
Vancouver
Coronell-Tovar A, Pardo JP, Rodríguez-Romero A, Sosa-Peinado A, Vásquez-Bochm L, Cano-Sánchez P, et al. Protein tyrosine phosphatase 1B ( PTP1B ) function, structure, and inhibition strategies to develop antidiabetic drugs. FEBS Letters. 2024;598(15):1811-1838. doi:10.1002/1873-3468.14901
BibTeX
@article{CoronellTovar2024,
author = {Coronell-Tovar, Andrea and Pardo, Juan P and Rodríguez-Romero, Adela and Sosa-Peinado, Alejandro and Vásquez-Bochm, Luz and Cano-Sánchez, Patricia and Álvarez-Añorve, Laura Iliana and González-Andrade, Martin},
title = {Protein tyrosine phosphatase 1B ( PTP1B ) function, structure, and inhibition strategies to develop antidiabetic drugs},
journal = {FEBS Letters},
year = {2024},
volume = {598},
number = {15},
pages = {1811--1838},
doi = {10.1002/1873-3468.14901}
}
EUVIMED